Aldeyra Therapeutics, Inc. (ALDX) 2018年年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 Form 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2018ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 19

2、34For transition period from to Commission File Number 001-36332 ALDEYRA THERAPEUTICS,INC.(Exact name of Registrant as specified in its charter)Delaware20-1968197(State or other jurisdictionof incorporation)(IRS EmployerIdentification No.)131 Hartwell Avenue,Suite 320Lexington,MA 02421(Address of pr

3、incipal executive offices)(781)761-4904(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Common Stock,$0.001 par value per share The Nasdaq Stock Market,LLC(Title of each class)(Name of each exchange on which registered)Securities registered

4、pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indi

5、cate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for suchshorter period that the registrant was required to file such reports),and(2)has been subject to such filing re

6、quirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the reg